Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer

Annals of Oncology

Volumn 11, Issue 6, 2000, Pages 673-678

  Belani, C P ^a   Einzig, A ^b   Bonomi, P ^c   Dobbs, T ^d   Capozzoli, M J ^a   Earhart, R ^e   Cohen, L J ^e   Luketich, J D ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Baptist Medical Center   (United States)

^e Aventis Pharmaceuticals   (United States)

Author keywords

Carboplatin; Docetaxel; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033735209     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008342116536     Document Type: Article

References (39)

1. Non-small-cell lung cancer
2. Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
3. Chemotherapy of lung cancer
4. Chemotherapy in non-small-cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials
5. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
6. Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of EORTC Early Clinical Trials Group
7. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
8. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
9. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer
10. Docetaxel and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC): A multicenter phase II trial
11. Early clinical studies with cis-diammine-1,1 cyclobutane-dicarboxylate platinum II
12. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
13. Carboplatin in non-small-cell lung cancer: The Cancer and Leukemia Group B experience
14. Docetaxel and carboplatin: A phase I and pharmacokinetic trial for advanced non-hematologic malignancies
15. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
16. Prediction of creatinine clearance from serum creatinine
17. Comprehensive criteria for assessing therapy-induced toxicity
18. Assessment of response to therapy in advanced breast cancer
19. One-sample multiple testing procedure for phase II clinical trials
20. Nonparametric estimation from incomplete observations
21. Docetaxel (taxotere) plus cisplatin: An active and well-tolerated combination in patients with advanced non-small-cell lung cancer
22. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
23. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
24. Docetaxel plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial (updated based on meeting slides)
25. The fine points of end points: Phase II trials in lung cancer
26. Efficacy and safety of docetaxel in clinical trials
27. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
28. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
29. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small-cell lung cancer: Results of a multicentre, phase II trial
30. Randomized phase III trial comparing cisplatin-etoposide versus carboplatin-paclitaxel in advanced and metastatic non-small-cell lung cancer (NSCLC)
31. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small-cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) Trial
32. Paclitaxel plus carboplatin in advanced non-smallcell lung cancer: A phase II trial
33. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
34. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC)
35. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastem Cooperative Oncology Group Trial
36. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small-cell lung cancer (NSCLC)
37. Phase II trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin for patients with advanced non-small-cell lung cancer (NSCLC)
38. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group